Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

“Renalism” with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review

Author(s): Hussein Al Sudani*, Samir Shah, Kevin Bryan Lo, Hani Essa, Ammaar Wattoo, Lucas Angelim, Sophia Brousas, Isabel Whybrow-Huppatz, Shaitalya Vellanki, Rajiv Sankaranarayanan and Janani Rangaswami

Volume 21, Issue 2, 2023

Published on: 07 April, 2023

Page: [106 - 110] Pages: 5

DOI: 10.2174/1570161121666230314114549

Price: $65

Abstract

Introduction: Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and mineralocorticoid receptor antagonists (MRA) reduce mortality and hospitalizations in heart failure with reduced ejection fraction (HFrEF) but their use is limited in advanced chronic kidney disease (CKD).

Methods: We carried out a systematic review of studies on HFrEF and CKD patients. The mean overall percentage of reported ACEI, ARB, MRA, and ARNI use, and the proportion of trials that included patients with advanced CKD grades 4-5 (estimated glomerular filtration rate (eGFR) <15-30 ml/min/1.73m2) were recorded per year. The proportion of trials with advanced CKD was logtransformed, and then fitted into a time regression model. The interactions between the proportion of trials that included CKD grades 4-5 and the proportion of reported use of ACEI, ARB, and MRAs per year were explored using Pearson’s correlation and univariate linear regression.

Results: A total of 706 articles were included; 76% reported background ACEI/ARB use, while 51% reported MRA use. ACEI/ARB use averaged 83% and MRA 50%. Of the trials, 57% included CKD grades 4-5. Over 10 years, the proportion of trials with CKD grades 4-5 increased while ACEI/ARB use decreased. MRA use rates remained about the same. There was an inverse association found between the proportion of trials with CKD grades 4-5 and ACEI/ARB use per year.

Conclusion: In the past 10 years, CKD grades 4-5 patients have been increasingly included in HFrEF clinical trials. Concurrently, ACEI/ARB use has reportedly decreased.

Next »
Graphical Abstract

[1]
Maddox TM, Januzzi JL Jr., Allen LA, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol 2021; 77(6): 772-810.
[http://dx.doi.org/10.1016/j.jacc.2020.11.022] [PMID: 33446410]
[2]
Patel RB, Fonarow GC, Greene SJ, et al. Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol 2021; 78(4): 330-43.
[http://dx.doi.org/10.1016/j.jacc.2021.05.002] [PMID: 33989713]
[3]
Kidney disease: Improving global outcomes (KDIGO) blood pressure work group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021; 99(3S): S1-S87.
[PMID: 33637192]
[4]
Lo KB, Essa H, Wattoo A, et al. Representation of chronic kidney disease in randomized controlled trials among patients with heart failure with reduced ejection fraction: A systematic review. Curr Probl Cardiol 2021; 101047.
[http://dx.doi.org/10.1016/j.cpcardiol.2021.101047] [PMID: 34785259]
[5]
Beltrami M, Milli M, Dei LL, Palazzuoli A. The treatment of heart failure in patients with chronic kidney disease: Doubts and new developments from the last ESC guidelines. J Clin Med 2022; 11(8): 2243.
[http://dx.doi.org/10.3390/jcm11082243] [PMID: 35456336]
[6]
Maini R, Wong DB, Addison D, Chiang E, Weisbord SD, Jneid H. Persistent underrepresentation of kidney disease in randomized, controlled trials of cardiovascular disease in the contemporary era. J Am Soc Nephrol 2018; 29(12): 2782-6.
[http://dx.doi.org/10.1681/ASN.2018070674] [PMID: 30389726]
[7]
Ortiz A, Navarro-González JF, Núñez J, et al. The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure. Clin Kidney J 2022; 15(5): 865-72.
[http://dx.doi.org/10.1093/ckj/sfab290] [PMID: 35498889]
[8]
Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004; 13(2): 163-70.
[http://dx.doi.org/10.1097/00041552-200403000-00004] [PMID: 15202610]
[9]
Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011) 2013; 3(1): 19-62.
[10]
Carracedo J, Alique M, Vida C, et al. Mechanisms of cardiovascular disorders in patients with chronic kidney disease: A process related to accelerated senescence. Front Cell Dev Biol 2020; 8: 185.
[http://dx.doi.org/10.3389/fcell.2020.00185] [PMID: 32266265]
[11]
McAlister FA, Ezekowitz J, Tarantini L, et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 2012; 5(3): 309-14.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.966242] [PMID: 22441773]
[12]
Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014; 35(7): 455-69.
[http://dx.doi.org/10.1093/eurheartj/eht386] [PMID: 24164864]
[13]
Hein AM, Scialla JJ, Edmonston D, Cooper LB, DeVore AD, Mentz RJ. Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. JACC Heart Fail 2019; 7(5): 371-82.
[http://dx.doi.org/10.1016/j.jchf.2019.02.009] [PMID: 31047016]
[14]
Banerjee D, Rosano G, Herzog CA. Management of heart failure patient with CKD. Clin J Am Soc Nephrol 2021; 16(7): 1131-9.
[http://dx.doi.org/10.2215/CJN.14180920] [PMID: 33495289]
[15]
Chen YL, Hang CL, Su CH, et al. Feature and impact of guideline-directed medication prescriptions for heart failure with reduced ejection fraction accompanied by chronic kidney disease. Int J Med Sci 2021; 18(12): 2570-80.
[http://dx.doi.org/10.7150/ijms.55119] [PMID: 34104088]
[16]
Cutshall BT, Duhart BT Jr, Saikumar J, Samarin M, Hutchison L, Hudson JQ. Assessing guideline-directed medication therapy for heart failure in end-stage renal disease. Am J Med Sci 2018; 355(3): 247-51.
[http://dx.doi.org/10.1016/j.amjms.2017.11.008] [PMID: 29549927]
[17]
Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007; 153(6): 1064-73.
[http://dx.doi.org/10.1016/j.ahj.2007.03.017] [PMID: 17540211]
[18]
Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110(6): 724-31.
[http://dx.doi.org/10.1161/01.CIR.0000138934.28340.ED] [PMID: 15289383]
[19]
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429-35.
[http://dx.doi.org/10.1056/NEJM198706043162301] [PMID: 2883575]
[20]
Riegger GAJ. Lessons from recent randomized controlled trials for the management of congestive heart failure. Am J Cardiol 1993; 71(17): E38-40.
[http://dx.doi.org/10.1016/0002-9149(93)90951-8] [PMID: 8328366]
[21]
Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362(9386): 772-6.
[http://dx.doi.org/10.1016/S0140-6736(03)14284-5] [PMID: 13678870]
[22]
Pitt B. Candesartan reduced mortality and hospital admissions in chronic heart failure. ACP J Club 2004; 140(2): 32-3.
[http://dx.doi.org/10.7326/ACPJC-2004-140-2-032] [PMID: 15122853]
[23]
Chertow GM, Normand SL, McNeil BJ. “Renalism”: Inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol 2004; 15(9): 2462-8.
[http://dx.doi.org/10.1097/01.ASN.0000135969.33773.0B] [PMID: 15339996]
[24]
Fröhlich H, Nelges C, Täger T, et al. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Am Heart J 2016; 178: 28-36.
[http://dx.doi.org/10.1016/j.ahj.2016.03.024] [PMID: 27502849]
[25]
Kane JA, Kim JK, Haidry SA, Salciccioli L, Lazar J. Discontinuation/dose reduction of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers during acute decompensated heart failure in african-american patients with reduced left-ventricular ejection fraction. Cardiology 2017; 137(2): 121-5.
[http://dx.doi.org/10.1159/000457946] [PMID: 28376504]
[26]
Barry AR. Managing heart failure with reduced ejection fraction in patients with chronic kidney disease: A case-based approach and contemporary review. CJC Open 2022; 4(9): 802-9.
[http://dx.doi.org/10.1016/j.cjco.2022.06.007] [PMID: 36148258]
[27]
van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 2022; 18(5): 294-306.
[http://dx.doi.org/10.1038/s41581-022-00535-6] [PMID: 35145275]
[28]
Lioudaki E, Joslin JR, Trachanatzi E, Androulakis E. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys. Rev Cardiovasc Med 2022; 23(3): 082.
[http://dx.doi.org/10.31083/j.rcm2303082] [PMID: 35345249]
[29]
Pitt B, Bushinsky DA, Kitzman DW, et al. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail 2018; 5(3): 257-66.
[http://dx.doi.org/10.1002/ehf2.12265] [PMID: 29369537]
[30]
Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015; 17(10): 1057-65.
[http://dx.doi.org/10.1002/ejhf.402] [PMID: 26459796]
[31]
Valdivielso JM, Balafa O, Ekart R, et al. Hyperkalemia in chronic kidney disease in the new era of kidney protection therapies. Drugs 2021; 81(13): 1467-89.
[http://dx.doi.org/10.1007/s40265-021-01555-5] [PMID: 34313978]
[32]
Banka G, Heidenreich PA, Fonarow GC. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. J Am Coll Cardiol 2013; 61(13): 1440-6.
[http://dx.doi.org/10.1016/j.jacc.2012.12.022] [PMID: 23433562]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy